{"url_path":"/sec/sxtc/10-k/2026/item-16g","section_key":"item-16g","section_title":"Item 16G CORPORATE GOVERNANCE","topic":"sec","document":{"doc_type":"20-F","doc_date":"2026-07-01","source_url":"https://www.sec.gov/Archives/edgar/data/1723980/0001213900-26-074310-index.html","accession_number":"0001213900-26-074310","cik":"0001723980","ticker":"SXTC","issuer_name":"China SXT Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1723980/0001213900-26-074310-index.html","primary_entity_key":"0001723980","primary_entity_name":"China SXT Pharmaceuticals, Inc."},"word_count":374,"has_tables":true,"body_markdown":"ITEM 16G. CORPORATE GOVERNANCE\n\n \n\nOur Class A Ordinary Shares\nare listed on the NASDAQ Capital Market, or NASDAQ. As such, we are subject to corporate governance requirements imposed by NASDAQ. Under\nNASDAQ rules, listed non-US companies such as ourselves may, in general, follow their home country corporate governance practices in\nlieu of some of the NASDAQ corporate governance requirements. A NASDAQ-listed non-US company is required to provide a general summary\nof the significant differences to its US investors either on the company website or in its annual report distributed to its US investors.\n\n \n\nOther than as described in\nthis section, our corporate governance practices do not differ from those followed by domestic companies listed on the NASDAQ Capital\nMarket. NASDAQ Listing Rule 5635 generally provides that shareholder approval is required of U.S. domestic companies listed on the NASDAQ\nCapital Market prior to issuance (or potential issuance) of securities (i) equaling 20% or more of the company’s common stock or\nvoting power for less than the greater of market or book value (ii) resulting in a change of control of the company; and (iii) which\nis being issued pursuant to a stock option or purchase plan to be established or materially amended or other equity compensation arrangement\nmade or materially amended. Notwithstanding this general requirement, NASDAQ Listing Rule 5615(a)(3)(A) permits foreign private issuers\nto follow their home country practice rather than these shareholder approval requirements. The British Virgin Islands laws do not require\nshareholder approval prior to any of the foregoing types of issuances. The Company, therefore, is not required to obtain such shareholder\napproval prior to entering into a transaction with the potential to issue securities as described above. The Board of Directors of the\nCompany has elected to follow the Company’s home country rules as to such issuances and will not be required to seek shareholder\napproval prior to entering into such a transaction. Rule 5620(a) requires each company listing common stock or voting preferred stock,\nor their equivalents, shall hold an annual meeting of shareholders no later than one year after the end of the issuer’s fiscal\nyear-end. The Company follows the home country practice and expect to hold annual shareholders meetings only if there are matters that\nrequire shareholders’ approval.\n\n \n\n110"}